Therapeutic short hairpin RNA expression in the liver: viral targets and vectors
Date: 6.4.2006
Over 500 million people worldwide are infected with one or more different and unrelated types of human hepatitis virus. Such individuals are at a high risk of developing acute or chronic hepatic disease, and ultimately dying from sequelae.
A promising new avenue currently being explored is to harness the power of RNA interference for development of an antiviral therapy. The timing to pursue this particular approach is excellent, with the first in vivo animal models for HCV infection becoming available, and the technology for liver-specific expression of short hairpin RNAs advancing at a rapid pace. Here, we critically review these important current developments, and discuss the next steps to bring this novel approach into the clinics.
"Source"[ http://www.nature.com/gt/journal/v13/n6/full/3302727a.html#Towards-antiviral-RNAi-therapeutics].
Related articles
Internalization of novel non-viral vector TAT-streptavidin into human cells - Background The cell-penetrating peptide derived from the Human immunodeficiency virus-1 transactivator protein Tat possesses the capacity to promote the effective uptake of various cargo molecules across the plasma membrane in vitro and in vivo (12.2.2007)
